We are live on ! Find out more
IRON icon

Disc Medicine

153 hedge funds and large institutions have $1.68B invested in Disc Medicine in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 15

65% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $2.24M

16% more funds holding

Funds holding: 132 → 153 (+21)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

14% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 44

2.83% less ownership

Funds ownership: 92.14% → 89.3% (-2.8%)

13% less capital inflows, than outflows

Capital inflows: $231M | Capital outflows: $267M

Holders
153
Holders Change
+21
Holders Change %
+15.91%
% of All Funds
2.01%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.1%
New
38
Increased
50
Reduced
44
Closed
15
Calls
$3.7​M
Puts
$2.24​M
Net Calls
+$1.46​M
Net Calls Change
+$1.9​M

IRON Hedge Fund Activity: Q4 2024 in Review

153 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q4 2024, worth a combined $1.68B — up 25% from $1.35B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new IRON positions and 15 closed out — a net gain of 23 holders — while 50 added to existing stakes and 44 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $84.4M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $47M.

  • 153 institutional investors held Disc Medicine (IRON) as of Q4 2024, up from 132 in Q3 2024.
  • Funds reported $1.68B of Disc Medicine stock for Q4 2024, up 25% quarter-over-quarter.
  • 38 funds opened new Disc Medicine positions in Q4 2024 and 15 closed out, a net change of +23 holders.
  • The largest Disc Medicine buyer in Q4 2024 was Fidelity Investments, an estimated $84.4M added.
  • The largest Disc Medicine seller in Q4 2024 was Bain Capital Life Sciences Investors, an estimated $47M sold.

Based on aggregated 13F filings for Q4 2024.